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Subclinical Hypothyroidism
A Review
Bernadette Biondi, MD; Anne R. Cappola, MD, ScM; David S. Cooper, MD
O verthypothyroidismispresentwhenserumthyroidhormonelevelsare lowerthanthereferencerange, indicatingthyroidinsufficiency. In overt hypothyroidism due to thyroid dys-
function (primaryhypothyroidism), thyrotropin (often referred toas
thyroid-stimulatinghormone,orTSH)levelsareappropriatelyelevated.
Subclinical hypothyroidismexistswhen serumthyroidhormone lev-
elsarewithin thereferencerange,butserumthyrotropin levelsareel-
evated outside the reference range.1 The diagnosis of subclinical hy-
pothyroidismisabiochemicaldiagnosis solelybasedonthyroid func-
tiontesting.Iniodine-sufficientpopulations,subclinicalhypothyroidism
affectsupto10%ofthepopulation,withthehighestprevalenceamong
womenandelderly individuals.2,3However, subclinicalhypothyroid-
ismfrequently reverts toeuthyroidism,4andthyrotropin levels riseas
peoplewithout thyroiddiseaseage,5-7making it likely that thepreva-
lence of subclinical hypothyroidismhas beenoverestimated.
Individualshavea rangeofvalues for serumthyrotropinandfree
thyroxine (FT4) thataremaintainedwithinanarrower rangethanthe
broaderpopulationreferencerange.8Becauseof theexquisitely sen-
sitive relationshipbetweenpituitary thyrotropinsecretionandserum
FT4 levels, an individual’s serumthyrotropin levelmaybehigher than
theupperlimitofthepopulation-basedreferencerangeifthat individu-
al’s serumFT4 level falls below that individual’s FT4 reference range,
even thoughhis/herFT4 level is stillwithin thepopulation-basedFT4
referencerange.This intraindividual thyroidaxissetpoint is largelyge-
neticallydetermined.9Thehypothalamic-pituitary-thyroidaxis ishighly
sensitive tominimal decrements in serum levels of thyroxine (T4), so
that decreases in FT4 levels, evenwithin the broadpopulation refer-
encerange,result in increasedsecretionofpituitarythyrotropin.How-
ever, insubclinicalhypothyroidism,duetothyroidinflammationorother
intrinsic thyroid disease, thyroidal hormonal output does not appro-
priately increase in responsetotheelevatedserumthyrotropin, lead-
ingtochronicallyelevatedthyrotropin levels.Subclinicalhypothyroid-
ismmaybecategorizedasgrade1whenthyrotropinlevelsarebetween
theupper limit of the reference range and9.9mU/L and as grade2 if
serumthyrotropin levelsare10mU/Lorhigher.10Approximately90%
ofpatientswithsubclinicalhypothyroidismhaveserumthyrotropinlev-
els lowerthan10mU/L.11,12Thisarticleprovidesacurrentreviewofthe
controversies relatedtotheclinical significance,diagnosis, andthera-
peutic considerations related to subclinical hypothyroidism. This re-
view does not cover subclinical hypothyroidism in women who are
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referred to as thyroid-stimulating hormone, or TSH) level with normal levels of free thyroxine
(FT4) affects up to 10% of the adult population.
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associatedwith iatrogenic thyrotoxicosis, especially in elderly patients, and there is no evidence
that it is beneficial in persons aged65 years or older.
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pregnantorareattemptingtobecomepregnant.Pregnancyandsub-
clinical hypothyroidism is covered elsewhere.13
Methods
We searched the PubMed database through March 13, 2019, for
English-language studies related to themanagement of subclinical
hypothyroidism. The searchwas updated onMay 30, 2019. Guide-
lines of major professional societies, meta-analyses, and random-
ized trials were prioritized for review. Selected articles weremutu-
ally agreed upon by the authors.
Differential Diagnosis of Elevated Serum
Thyrotropin Levels
Mild thyroid failuredue to autoimmune thyroiditis is themost com-
moncauseofmildly elevated serumthyrotropin levels.Althoughel-
evated serum thyrotropin levels are characteristic of primary thy-
roid failure,otherclinical conditions (eg,external radiotherapy to the
neck), drugs (eg, lithium), or laboratory anomalies (eg, hetero-
philic antibodies in the serum)may result in elevated serum thyro-
tropin levels (Box). The most important of these is the increase in
serum thyrotropin levels, which is likely a normal consequence of
aging. Epidemiological studieshave showna rise in serumthyrotro-
pin levels (usually <8mU/L) in healthy elderly peoplewithout clini-
cal or biochemical evidence of intrinsic thyroid disease.5 The cause
of the increase in serum thyrotropin is uncertain, but it is clear that
older individualswhohavemildly elevated serumthyrotropin in the
absenceof thyroiddiseasearenot at riskof increasedmorbidity and
mortality.7,14 Some studies suggest that elevated serum thyrotro-
pin levels in this context are associated with better health out-
comesand improvedfunctional status.15,16Otherconditionsthatmay
lead tomildelevations in serumthyrotropin that canmimic subclini-
cal hypothyroidism include untreated adrenal insufficiency,1muta-
tions in the thyrotropin receptor protein on thyroid follicular cells
causing “thyrotropin resistance,”17 and extreme obesity (ie, body
mass index (BMI [calculatedasweight inkilogramsdividedbyheight
in meters squared], >40 to 45).18 The latter is probably due to the
effects of leptin, a hormone secreted by adipose tissue, on hypo-
thalamic thyrotropin-releasing hormone secretion, leading to in-
creased levels of serum thyrotropin.19,20Obesity-related increases
in serum thyrotropin are reversiblewithweight loss but canbeper-
ceived as hypothyroidism-related overweight.20 In critically ill hos-
pitalized patients, serum thyrotropin levels can be suppressed due
to the effects of cytokines and other factors on the hypothalamic-
pituitary-thyroid axis, as part of the disorder known as the “euthy-
roid sick syndrome.” During recovery, serum thyrotropin levels can
rebound, but levels rarely are more than 10mU/L.21 In this setting,
the diagnosis of hypothyroidism should be deferred until the pa-
tient has fully recovered.22 In patients undergoing thyroid lobec-
tomy for benignormalignant thyroid nodules, there is often a tran-
sientrise inserumthyrotropinpostoperativelythatcan last forseveral
months. Permanent hypothyroidism, which is typically subclinical,
canoccur inup to60%ofpatients after thyroid lobectomyandmay
occurmore than 1 year after surgery. Patientswithpreoperative se-
rum thyrotropin levels higher than approximately 2 mU/L, espe-
cially if thyroid peroxidase (TPO) antibodies are present, are more
likely to develop postoperative hypothyroidism.23,24
Depending on the assay system, serum thyrotropin levels can
beelevateddue to ameasurement artifact inpatientswith circulat-
ing antibodies tomouse immunoglobulin calledHAMA (human an-
timouse antibodies).25 Artifactual elevations in serum thyrotropin
canalsobe seen inpatientswhohave circulatingmacroTSH (similar
to macroprolactin), in which thyrotropin is complexed to antithy-
rotropic IgG to formahighmolecular–weight complexwith lowbio-
logical activity.26TheprevalenceofmacroTSH isnotwelldelineated,
but it might be present in as many as 1% to 2% of patients diag-
nosed with subclinical hypothyroidism.26
Risk of Progression to Overt Disease
In 60% of patients with grade 1 subclinical hypothyroidism, thyro-
tropindeclines to thenormal rangeover5years.27,28Theannual rate
Box. Differential Diagnosis of Elevated Serum Thyrotropin
and Normal Serum Free Thyroxinea
Subclinical HypothyroidismDue toMild Thyroid Failure
Chronic lymphocytic thyroiditis (Hashimoto thyroiditis)
Inadequate levothyroxine replacement therapy for overt
hypothyroidism
Following thyroid lobectomy
Followingantithyroiddrugor radioiodine therapy forhyperthyroidism
Following external beam radiotherapy to the head and neck
Infiltrative disorders such as amyloidosis and Riedel thyroiditis
Following an episode of subacute (granulomatous) thyroiditis
Drug induced, especially in patients with underlying lymphocytic
thyroiditis
Lithium carbonate
Iodine-containing compounds, including amiodarone
Interferon alfa
Tyrosine kinase inhibitors, immune check point inhibitors
Physiological Transient Rises in Thyrotropin Levels
Recovery after severe nonthyroidal illness
During recovery from various forms of thyroiditis
Following withdrawal of chronic levothyroxine therapy in
a euthyroid individual
Seasonal (wintertime) increases in serum thyrotropin
Elevated SerumThyrotropin Levels
That AreNot True Subclinical Hypothyroidism
Common causes
Increases in elderly persons without thyroid disease
Increases in patients with marked obesity, typically with body
mass index of more than 40
Uncommon causes
Anomalous laboratory results due to heterophilic antibodies
or macroTSH
Untreated adrenal insufficiency
Abbreviation: TSH indicates thyroid-stimulating hormone (thyrotropin).
a Modified from Cooper and Biondi.1
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of progression to overt disease is about 2% to 4% in such patients,
dependingonTPOantibodystatus.28-31 Inelderlyparticipants (65
years) enrolled in the Cardiovascular Health Study,4 the rate of thy-
rotropin normalization over 2 years was 46% in participants with
grade 1 subclinical hypothyroidismwith thyrotropin levels of 4.5 to
6.9 mU/L compared with 7% for grade 2 subclinical hypothyroid-
ism. Normalization occurred in 48% of participants with subclini-
cal hypothyroidismwhodid not have TPO) antibodies. Conversely,
grade2subclinicalhypothyroidism isassociatedwith increasedrates
of progression to overt hypothyroidism, especially in women and
inpatientswithpositiveTPOantibodies.32,33 In 1prospectivestudy,29
40%ofpatientswithbaseline thyrotropin levels of 10 to 14.9mU/L
and85%with thyrotropin levels of 15 to 19.9mU/Ldevelopedovert
hypothyroidism during a mean follow-up period of 31.7 months.
Clinical Manifestations
Grade 1 subclinical hypothyroidism is rarely associated with hypo-
thyroid and neuropsychiatric symptoms or alterations in mood or
cognition.1,28 New onset of symptoms of hypothyroidism, espe-
ciallywhennumerous and severe, usually suggests thediagnosis of
grade2subclinicalhypothyroidismorovertdisease.34Althoughqual-
ity of life is not altered in patients with subclinical hypothyroidism
comparedwith euthyroid controls,35 amild impairment of declara-
tive, working memory, and mood has been reported in middle-
agedpatientswithgrade2 subclinical hypothyroidism.36Nosignifi-
cant difference in depressive symptoms has been found between
euthyroid and subclinical hypothyroidism patients.37,38
Inelderly individuals,hypothyroidsymptomsusually fail to iden-
tify thyroidhormonedeficiency, even inoverthypothyroidism.39At
baseline, participants enrolled in the Thyroid Hormone Replace-
ment for Untreated Older Adults With Subclinical Hypothyroidism
(TRUST) trial40 involving737adults65yearsorolder (meanage,74.4
years; mean thyrotropin, 6.40 mU/L) had hypothyroid symptom
scores similar to or lower than the general population.
Clinical Significance
Cardiovascular Risk
Cardiovascularabnormalities(leftventricularsystolicanddiastolicdys-
function and impaired vascular relaxation) have been described in
patients with grade 1 and grade 2 subclinical hypothyroidism.41 A
meta-analysis42 involving 675 patients younger than 60 years re-
portedthatpatientswithsubclinicalhypothyroidism,eventhosewith
milddisease,hadsignificantlyworseparametersof leftventriculardia-
stolic function assessed by tissue Doppler echocardiography when
comparedwithahealthycontrolgroupmatchedforageandsex.The
slowed rate of left ventricular relaxation may impair ventricular fill-
ingduringexercise, leadingto leftventricularsystolicdysfunctionand
impairing the physical activity of patients with subclinical
hypothyroidism.28 Vascular abnormalities, such as increased sys-
temic vascular resistance and altered endothelial-mediated vasore-
laxation and vascular compliance have also been reported in pa-
tients with grade 1 and grade 2 subclinical hypothyroidism.43
Hypothyroidism is one of the most frequent secondary causes
of dyslipidemia (elevated low-density lipoprotein [LDL] cholesterol
and triglyceride levels), and screening for hypothyroidism is recom-
mended for individuals with hypercholesterolemia.44 Metabolic al-
terations can develop in grade 2 subclinical hypothyroidism, espe-
cially in patients with insulin resistance.45 A meta-analysis46 of 16
observational studies confirmed alterations in lipid pattern (in-
creased concentrations of serum total cholesterol, LDL cholesterol,
and triglyceride levels) in patients with grade 2 subclinical hypothy-
roidism;weakerevidencewasfoundfortheassociationwithHDLcho-
lesterol levels.Adverseconsequencesof insulinresistanceandchanges
in lipid metabolismmay contribute to a higher prevalence of nonal-
coholic fatty liver disease (NAFLD) across the spectrum of hypothy-
roidism, although the incidence of NAFLD was not increased in a
meta-analysis47 involving patients with subclinical hypothyroidism.
Grade2subclinicalhypothyroidismwasassociatedwith increasedca-
rotid intima-media thickness (CIMT) in a meta-analysis48 involving
3602 patients. A higher CIMTwas found among adult patients with
grade 2 subclinical hypothyroidism comparedwithmild disease and
euthyroid controls in ameta-analysis of 12 trials.49
These alterations inmyocardial function,metabolic profile, and
vascular functionsuggest thatpatientswithuntreatedsubclinicalhy-
pothyroidismmaybeat increased riskofadversecardiovascularout-
comes.However, individual-patientmeta-analysisperformedbythe
Thyroid Studies Collaboration,11,50-52 a consortiumof cohort studies
withdata frommore than75000participants, didnotdemonstrate
anassociationofsubclinicalhypothyroidismwithincreasedriskofatrial
fibrillation,52heart failure,50stroke,51 coronaryheartdiseaseevents,11
mortalityfromcoronaryheartdisease,11oroverallmortality11compared
with euthyroid individuals (Table). In contrast, when datawere ana-
lyzed, stratifiedbydegreeof thyrotropinelevation, thyrotropin levels
of 10mU/Lorhigherwereassociatedwith increasedriskofheart fail-
ure,coronaryheartdiseaseevents,andmortality fromcoronaryheart
diseasecomparedwithnormalthyrotropinvalues.11,50 Inaddition,thy-
rotropinvaluesof7.0to9.9mU/Lwereassociatedwith increasedrisk
of fatal strokeandmortality fromcoronaryheartdisease.11,51Thepres-
enceofTPOantibodieswasnotassociatedwithhigherriskofcoronary
heartdiseaseeventsbeyondthedegreeofthyrotropinelevation.53The
findings fromthesestudiessuggest that theseverityofsubclinicalhy-
pothyroidism isassociatedwithgreater cardiovascular risk.One limi-
tationcommontoallthecohortsincludedinthesemeta-analysesisthat
thyroid functiontestingwasonlyperformedatonetimepoint, result-
ing inanalysisofparticipantswith transientandpersistentsubclinical
hypothyroidism together. A separate analysis54 conducted in one of
thecohortswith repeatedmeasuresof thyroid functionshowedthat
persistent subclinical hypothyroidismwas not associatedwith coro-
nary heart disease, heart failure, or cardiovascular death, similar to
analyses using a single thyroid functionmeasurement.
Cognitive Decline and Dementia
A meta-analysis55 including prospective and cross-sectional stud-
ies supports an association of subclinical hypothyroidism with
cognitive impairment in patients younger than 75 years, but no as-
sociation in persons who are older than 75 years. This is consistent
with 2 other studies. In one, amild serum thyrotropin increasewas
not associatedwith cognitivedysfunction, anxiety, or depression in
participants 65 years or older.56 In the other, a meta-analysis57 in-
cluding 11 prospective cohorts involving patients with a mean age
of 65 years or older, there was no association between subclinical
hypothyroidism and dementia or a decline in cognition.
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Kidney Function
Thyroidhormonedeficiencycanworsenrenalhemodynamicsbyde-
creasing cardiac output, leading to a progressive decline in glomer-
ular filtration rate. In a meta-analysis58 of 16 studies, there was no
associationbetween subclinical hypothyroidismanddecline in kid-
ney function. However, in patients with renal failure requiring he-
modialysis, subclinical hypothyroidismwas associated with higher
mortality than with the euthyroid state.59
Musculoskeletal Outcomes
Among elderly patients, there was no association of subclinical hy-
pothyroidismwith bonemineral density or fracture risk compared
with euthyroid controls in 2 meta-analyses.12,60 There was also no
consistentassociationbetweensubclinicalhypothyroidismandfrailty
either at baseline or during follow-up in community-dwelling el-
derly people.61
Women Undergoing Assisted Reproductive
Technologies
Ameta-analysis62of4 randomizedclinical trials (RCTs) involving787
infertile couplesundergoingvitro fertilization (IVF)or intracytoplas-
mic sperm injection (ICSI) therapies did not find an association of
levothyroxine therapywith improved conception or live birth rates
in women with subclinical hypothyroidism. The American Thyroid
Association recommends thatwomenwith subclinical hypothyroid-
ism who are undergoing IVF or ICSI be treated with LT4 to achieve
a serum thyrotropin concentration of 2.5 mU/L.13
Treatment Rationale
Possible indications for treating subclinical hypothyroidism in-
clude improvement in symptoms,preventionofoverthypothyroid-
ism,andpreventionofadverseevents (Figure).Thesepotentialben-
efitsof thyroidhormonesupplementationshouldbeweighedagainst
the risks of reducing thyrotropin values below the reference range
and causing iatrogenic subclinical or overt hyperthyroidism. Ran-
domized trials of treatment of subclinical hypothyroidismhave not
focused specifically on patients with symptoms of hypothyroid-
ism. The largest trial to date, the TRUST trial,40 did not demon-
strate symptomatic benefit to treatment of older individuals with
subclinicalhypothyroidism.TheTRUSTtrial randomized737menand
women65years andolderwithpersistent subclinical hypothyroid-
ism to levothyroxine or placebo. Therewas no effect of levothyrox-
ine on the coprimary outcomes of hypothyroid symptoms and fa-
tigue scores after 12 months of therapy nor on the secondary
outcomes of quality of life, handgrip strength, cognitive function,
blood pressure, weight, BMI, waist circumference, CIMT, or carotid
Figure. General Therapeutic Approach to theManagement of Subclinical Hypothyroidism inNonpregnant Adults
Diagnosis of an elevated serum thyrotropin (TSH) level in a nonpregnant adult
Treatment initiation considerations3
1
If treatment is initiated, measure thyrotropin level in 6 weeks and adjust LT4 dose if necessary.
Once target thyrotropin level is reached, perform annual measurement to confirm that it remains within the target range.
4
Patients <65 yearsThyrotropinlevel, mU/L Patients ≥65 years
7.0-9.9 Consider treatment
 with LT4 
to reduce risk of CHD mortalitya
Treat with LT4 to reduce risk of fatal stroke 
and coronary heart disease (CHD) mortalitya
≥10.0 Treat
 with LT4 to reduce risk of progression to overt hypothyroidism, heart failure, 
CHD events, and CHD mortalitya
4.5-6.9
Measure thyroid peroxidase (TPO) antibodies
Annual follow-up thyrotropin measurement
of asymptomatic patients
Consider treatment with levothyroxine (LT4)
in patients with
Multiple symptoms of hypothyroidism
Positive TPO antibodies
Progressively increasing thyrotropin levels
A plan for pregnancy
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Treatment is not recommended
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Treatment follow-up
Initial thyrotropin level 4.5-14.9 mU/L, repeat measurement and document normal free thyroxine level in 1-3 months.
Initial thyrotropin level ≥15 mU/L, repeat measurement and document normal free thyroxine level in 1-2 weeks.
2 Confirmation of persistent subclinical hypothyroidism
a Recommendation is based on an
association of subclinical
hypothyroidismwith increased
rates to the outcomes listed
and is not based on clinical trial
evidence that treatment can reduce
these outcomes.
TSH indicates thyroid-stimulating
hormone.
Subclinical Hypothyroidism—A Review Review Clinical Review& Education
jama.com (Reprinted) JAMA July 9, 2019 Volume 322, Number 2 157
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Johns Hopkins University User  on 07/10/2019
plaque thickness.40 The majority of participants had grade 1 sub-
clinical hypothyroidism(meanbaseline thyrotropin,6.4mU/L), and
the levothyroxine dose was low (median dosage, 50 μg/d), reduc-
ing the thyrotropin level by approximately 2mU/L.Noexcessof ad-
verse events or hyperthyroid symptomswas observed in the levo-
thyroxinegroup.40Ameta-analysis63of21 trials including theTRUST
trial found no difference in general quality of life or thyroid-related
symptoms between participants with subclinical hypothyroidism
treated with levothyroxine compared with placebo. No difference
was found formultiple secondary outcomes, including depression,
cognitive function testing, fatigueor tiredness,muscle strength, sys-
tolic blood pressure, or BMI.63 One meta-analysis49 of 12 random-
ized trials that did not include the TRUST trial found that treatment
with levothyroxine was associated with decreased CIMT and im-
proved lipid profile.
In contrast, in a substudyof theTRUST trial,64participantswho
were taking levothyroxinehadnodifference inCIMTafter 18months
of therapycomparedwith theplacebogroup.TheUSPreventiveSer-
vices Task Force65 found a potential treatment benefit of levothy-
roxineon lipidsbut reported that theeffectswere inconsistent, not
statistically significant inmost studies, and of uncertain clinical sig-
nificance. None of the randomized trials to date has had sufficient
power to examine the effects of treatment of subclinical hypothy-
roidism on end points such as incidence of cardiovascular events,
dementia,or fracture.Thesestudiesprovidestrongevidenceagainst
treating anunselectedgroupof elderly patientswith subclinical hy-
pothyroidism. However, whether these findings can be extrapo-
lated to patients withmoremarked symptoms of hypothyroidism,
thosewithgrade2subclinicalhypothyroidism,or individualsyounger
than 65 years is not known.
One retrospective study66 of individuals with mild subclinical
hypothyroidism reported an association of levothyroxine treat-
ment, compared with nontreatment, with lower all-cause mortal-
ity and reduced ischemicheart diseaseevents inpatientswhowere
younger (40-70 years), but not in patients older than 70 years. In
another similarlydesignedstudy,67 levothyroxine treatmentwasas-
sociatedwith a reduction in all-causemortality in patients younger
than65yearsbutnotmyocardial infarctionor cardiovascular death
in this age group and not with these outcomes in older patients.
As mentioned previously, progression rates to overt hypothy-
roidism are low in patients with grade 1 subclinical hypothyroidism
(2%-4%per year, depending on TPOpositivity), and observational
studies donot showan increase in adverse events in this subgroup.
These findings in conjunction with the clinical trial results support
continued observation instead of treating asymptomatic patients
with grade 1 subclinical hypothyroidism.Despite potential benefits
of treatment on lipid levels and echocardiographic parameters, no
randomized trials have had sufficient statistical power to examine
cardiovascular events and observational data have focused onpar-
ticipants without preexisting cardiovascular disease. In the ab-
sence of sufficient clinical trial information in patients with grade 2
subclinical hypothyroidism(thyrotropin10mU/L), thehigh riskof
progression to overt hypothyroidism and observational data dem-
onstrating increased cardiovascular risk without treatment pro-
vide the rationale to treat this subgroup of patients (Figure). Initia-
tion of treatment can be considered for patientswith a thyrotropin
level of 7.0 to 9.9 mU/L based on observational data indicating in-
creased cardiovascular risk, and a therapeutic trial of levothyroxine
canbeconsidered forpatientswithgrade 1 subclinical hypothyroid-
ismwho have substantial symptoms.
Method of Treatment
Becausesubclinicalhypothyroidismis frequently transient,27 it is rec-
ommended that a second abnormal thyrotropin level be con-
firmed 1 to3months after the initial test andprior to initiating treat-
ment. If the initial thyrotropin value is more than 15 mU/L, testing
should be repeated in 1 to 2 weeks. The FT4 measurement should
also be performed at the same time as follow-up testing for thyro-
tropin levels. Normalization of serum thyrotropin is the goal of
therapy in patientswho are treated for subclinical hypothyroidism.
Levothyroxine is the treatment of choice.68-71 Because the degree
of thyroid dysfunction is mild, small (eg, 25-75 μg) doses of levo-
thyroxine are adequate to restore normal serum thyrotropin levels
in the majority of nonpregnant patients. Serum thyrotropin levels
should be assessed 6 weeks after initiating the medication, and at
6-week intervals after subsequent changes in themedicationdose.
Once the thyrotropin targethasbeenachieved, annual thyroid func-
tion tests are recommended to document that serum thyrotropin
is stillwithin thetarget range. Importantly, anunacceptablyhighpro-
portionofpatients treatedwith levothyroxine (15%-38%)havebeen
found tohave thyrotropin levels lower than the reference range, in-
dicating over replacement and emphasizing the need for contin-
uedmonitoring of serum thyrotropin levels.72,73 Risks of overtreat-
ment (iatrogenic thyrotoxicosis) areparticularlyproblematic inolder
patients and postmenopausal women and include atrial fibrilla-
tion, osteoporosis, and fractures.74Because thebenefits of therapy
areperhaps the lowest inpersons65yearsorolder andbecause this
group is most susceptible to the dangers of overtreatment, treat-
ment should be individualized and implemented cautiously in this
age group (Figure).
Guidelinesvarywithrespect tothetarget thyrotropin,withsome
recommending target thyrotropin levels within the reference
range68,69 and others recommending thyrotropin levelswithin the
lowerpartof the reference range innonelderlypatients.70,71,75There
is no evidence that adjusting the dose of levothyroxine to alter se-
rumthyrotropin levelswithin the reference range results in improve-
ment in persistent symptoms or metabolic function.76-78 Some
guidelines recommend relaxation of thyrotropin targets for elderly
patients to 1 to 5 mU/L70 or 4 to 6 mU/L.69,71 If treatment is with-
held, annualmonitoring of serum thyrotropin levels seems reason-
able. Unfortunately, even though there are clinical practice guide-
lines that make specific recommendations about subclinical
hypothyroidismmanagement, there are large knowledgegapsdue
to the absenceof large randomized trials that include symptomatic
patients with a spectrum of ages and serum thyrotropin levels.
Conclusions
Subclinicalhypothyroidismiscommonandmost individualscanbeob-
servedwithout treatment.Treatmentmightbe indicated forpatients
withsubclinicalhypothyroidismandserumthyrotropinlevelsof10mU/L
orhigheror foryoungandmiddle-aged individualswithsubclinicalhy-
pothyroidismand symptomsconsistentwithmildhypothyroidism.
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